{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T06:27:49Z","timestamp":1786429669329,"version":"build-2736575974"},"reference-count":74,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Differentiating Alzheimer\u2019s disease (AD) from both Parkinson\u2019s disease (PD) and Lewy body dementia (DLB) is difficult due to their clinical similarities. Plasma biomarkers offer an alternative to neuroimaging and cerebrospinal fluid analysis; however, there are limitations with respect to differential diagnosis of AD, PD, and DLB with current clinical assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Here we used machine learning to assess plasma miRNAs for their specificity in diagnosing AD vs. PD, and DLB. Our multi-center study assayed 57 AD-associated miRNAs in human plasma from 82 cognitively normal controls (NC), 87 AD, 100 PD, and 20 DLB. Predictive models generated by three independent machine learning methods were evaluated by cross-validated ROC curves [cvAUC (bootstrap bias-corrected 95% CI)]. We also used linear discriminant analysis with all 57 miRNAs to identify a model that best separates AD from PD + DLB participants and DLB from AD+PD participants. Further, we used Target prediction and Ingenuity Pathway Analysis to identify highly relevant mRNA targets of the miRNAs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Individual assessment of the 57 miRNAs identified a subset of 10 miRNAs that were more AD-specific, and 23 miRNAs that were more PD and\/or DLB associated. Ridge logistic regression predictive models with the 10 AD-specific miRNAs had good performance for separating AD vs. PD and DLB (cvAUC = 0.77 [0.70, 0.83]) and AD vs. PD (cvAUC = 0.79 [0.71, 0.85]), but not for AD vs. DLB (cvAUC = 0.58 [0.43, 0.79]). By developing a predictive model using data from all 57 miRNAs and elastic-net regression we achieved good separation of AD from PD (cvAUC = 0.80 [0.72, 0.86]) and DLB (cvAUC = 0.77 [0.64, 0.87]) with a subset of six miRNAs (miRs-19a-3p, 22-3p, 92b-3p, 101-3p, 143-3p, 423\u20135p) identified as the most important to these models. The linear discriminant analysis model achieved very good classification of AD vs. PD + DLB (cvAUC = 0.94 [0.87, 0.97]), PD from AD+DLB (cvAUC = 0.88 [0.80, 0.92]), and DLB from AD+PD (cvAUC = 0.85 [0.78, 0.89]) with miR-26a-5p and 146a-5p being most important for AD vs. PD + DLB, and miR-142-3p and 101-3p being most important for DLB vs. AD+PD. Target prediction and Ingenuity Pathway Analysis with miR-26a-5p, 146a-5p, 142-3p, 101-3p returned highly relevant mRNA targets associated with tauopathy, dementia, and movement disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>These data demonstrate that predictive modeling using plasma miRNA expression data may improve the differential diagnosis of AD from PD from DLB.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnagi.2026.1788991","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T05:35:22Z","timestamp":1786426522000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Plasma multi-miRNA models classify Alzheimer\u2019s, Parkinson\u2019s, and Lewy body dementia"],"prefix":"10.3389","volume":"18","author":[{"given":"Ursula S.","family":"Sandau","sequence":"first","affiliation":[{"name":"Department of Anesthesiology & Perioperative Medicine, Oregon Health & Science University","place":["Portland, OR, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack T.","family":"Wiedrick","sequence":"additional","affiliation":[{"name":"Biostatistics & Design Program, Oregon Health & Science University","place":["Portland, OR, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor J.","family":"McFarland","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology & Perioperative Medicine, Oregon Health & Science University","place":["Portland, OR, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dora","family":"Yearout","sequence":"additional","affiliation":[{"name":"Geriatric Research, Education, and Clinical Center, VA Puget Sound Health Care System","place":["Seattle, WA, United States"]},{"name":"Department of Neurology, University of Washington","place":["Seattle, WA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrus P.","family":"Zabetian","sequence":"additional","affiliation":[{"name":"Geriatric Research, Education, and Clinical Center, VA Puget Sound Health Care System","place":["Seattle, WA, United States"]},{"name":"Department of Neurology, University of Washington","place":["Seattle, WA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Ching","family":"Hu","sequence":"additional","affiliation":[{"name":"Geriatric Research, Education, and Clinical Center, VA Puget Sound Health Care System","place":["Seattle, WA, United States"]},{"name":"Department of Neurology, University of Washington","place":["Seattle, WA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debby W.","family":"Tsuang","sequence":"additional","affiliation":[{"name":"Geriatric Research, Education, and Clinical Center, VA Puget Sound Health Care System","place":["Seattle, WA, United States"]},{"name":"Department of Psychiatry and Behavioral Sciences, University of Washington","place":["Seattle, WA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Quinn","sequence":"additional","affiliation":[{"name":"Department of Neurology, Oregon Health & Science University","place":["Portland, OR, United States"]},{"name":"Parkinson Center and Movement Disorders Program, Oregon Health & Science University","place":["Portland, OR, United States"]},{"name":"Portland VAMC Parkinson's Disease Research, Education, and Clinical Center","place":["Portland, OR, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Saugstad","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology & Perioperative Medicine, Oregon Health & Science University","place":["Portland, OR, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"111961","DOI":"10.1016\/j.exger.2022.111961","article-title":"Sera miR-34a, miR-29b and miR-181c as potential novel diagnostic biomarker panel for Alzheimers in the Egyptian population","volume":"169","author":"Abuelezz","year":"2022","journal-title":"Exp. Gerontol."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"7361","DOI":"10.1002\/alz.14167","article-title":"The Alzheimer's disease neuroimaging initiative clinical core","volume":"20","author":"Aisen","year":"2024","journal-title":"Alzheimers Dement."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e1708","DOI":"10.1212\/WNL.0000000000207755","article-title":"Association of plasma phosphorylated tau with the response to neflamapimod treatment in patients with dementia with Lewy bodies","volume":"101","author":"Alam","year":"2023","journal-title":"Neurology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/ana.26453","article-title":"Alpha-synuclein seed amplification in CSF and brain from patients with different brain distributions of pathological alpha-synuclein in the context of co-pathology and non-LBD diagnoses","volume":"92","author":"Arnold","year":"2022","journal-title":"Ann. Neurol."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"20947","DOI":"10.1038\/s41598-021-00424-1","article-title":"Dementia subtype prediction models constructed by penalized regression methods for multiclass classification using serum microRNA expression data","volume":"11","author":"Asanomi","year":"2021","journal-title":"Sci. Rep."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1228927","DOI":"10.3389\/fnins.2023.1228927","article-title":"Common microRNA regulated pathways in Alzheimer's and Parkinson's disease","volume":"17","author":"Awuson-David","year":"2023","journal-title":"Front. Neurosci."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s10571-019-00751-y","article-title":"Specific signatures of serum miRNAs as potential biomarkers to discriminate clinically similar neurodegenerative and vascular-related diseases","volume":"40","author":"Barbagallo","year":"2020","journal-title":"Cell. Mol. Neurobiol."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3109\/1354750X.2013.814073","article-title":"MicroRNA in Alzheimer's disease: an exploratory study in brain, cerebrospinal fluid and plasma","volume":"18","author":"Bekris","year":"2013","journal-title":"Biomarkers"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/cells11121882","article-title":"MicroRNA networks in cognition and dementia","volume":"11","author":"Blount","year":"2022","journal-title":"Cells"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e94839","DOI":"10.1371\/journal.pone.0094839","article-title":"Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimer's and Parkinson's diseases correlate with disease status and features of pathology","volume":"9","author":"Burgos","year":"2014","journal-title":"PLoS One"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.3233\/JAD-230572","article-title":"Extracellular vesicle-enriched miRNA-biomarkers show improved utility for detecting Alzheimer's disease dementia and medial temporal atrophy","volume":"99","author":"Chai","year":"2024","journal-title":"J. Alzheimer's Dis"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1038\/mp.2014.127","article-title":"Prognostic serum miRNA biomarkers associated with Alzheimer's disease shows concordance with neuropsychological and neuroimaging assessment","volume":"20","author":"Cheng","year":"2015","journal-title":"Mol. Psychiatry"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1766822","DOI":"10.1080\/20013078.2020.1766822","article-title":"Small RNA fingerprinting of Alzheimer's disease frontal cortex extracellular vesicles and their comparison with peripheral extracellular vesicles","volume":"9","author":"Cheng","year":"2020","journal-title":"J. Extracell. Vesicles"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"15016","DOI":"10.1021\/acs.nanolett.4c03768","article-title":"Blood-based nanoparticle-enhanced quaking-induced conversion (Nano-QuIC): inhibitor-resistant detection of seeding activity in patients diagnosed with Parkinson's disease","volume":"24","author":"Christenson","year":"2024","journal-title":"Nano Lett."},{"key":"ref15","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e70213","DOI":"10.1002\/dad2.70213","article-title":"A plasma miRNA signature, including miR-495, as early diagnostic biomarkers associated with cognitive decline in Alzheimer's disease","volume":"17","author":"Cots","year":"2025","journal-title":"Alzheimers Dement (Amst)"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e0197329","DOI":"10.1371\/journal.pone.0197329","article-title":"Specific serum and CSF microRNA profiles distinguish sporadic behavioural variant of frontotemporal dementia compared with Alzheimer patients and cognitively healthy controls","volume":"13","author":"Denk","year":"2018","journal-title":"PLoS One"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.parkreldis.2015.11.014","article-title":"Identification of a panel of five serum miRNAs as a biomarker for Parkinson's disease","volume":"22","author":"Ding","year":"2016","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1007\/s12035-021-02323-y","article-title":"Profiling of serum exosome MiRNA reveals the potential of a MiRNA panel as diagnostic biomarker for Alzheimer's disease","volume":"58","author":"Dong","year":"2021","journal-title":"Mol. Neurobiol."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"625659","DOI":"10.1155\/2015\/625659","article-title":"Serum MicroRNA profiles serve as novel biomarkers for the diagnosis of Alzheimer's disease","volume":"2015","author":"Dong","year":"2015","journal-title":"Dis. Markers"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/jgs.18124","article-title":"Conversion between the Montreal cognitive assessment and the Mini-mental status examination","volume":"71","author":"Fasnacht","year":"2023","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9091272","article-title":"Platelet miRNA biosignature discriminates between dementia with Lewy bodies and Alzheimer's disease","volume":"9","author":"Gamez-Valero","year":"2021","journal-title":"Biomedicine"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40035-019-0169-5","article-title":"Exploratory study on microRNA profiles from plasma-derived extracellular vesicles in Alzheimer's disease and dementia with Lewy bodies","volume":"8","author":"Gamez-Valero","year":"2019","journal-title":"Transl Neurodegener"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.3233\/JAD-170343","article-title":"A 9-microRNA signature in serum serves as a noninvasive biomarker in early diagnosis of Alzheimer's disease","volume":"60","author":"Guo","year":"2017","journal-title":"J. Alzheimer's Dis"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13578-023-01190-5","article-title":"Exploring small non-coding RNAs as blood-based biomarkers to predict Alzheimer's disease","volume":"14","author":"Gutierrez-Tordera","year":"2024","journal-title":"Cell Biosci."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1637368","DOI":"10.3389\/fnagi.2025.1637368","article-title":"miR-423-5p and miR-92a-3p in Alzheimer's disease: relationship with pathology and cognition","volume":"17","author":"Han","year":"2025","journal-title":"Front. Aging Neurosci."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3233\/JAD-122350","article-title":"A study of small RNAs from cerebral neocortex of pathology-verified Alzheimer's disease, dementia with lewy bodies, hippocampal sclerosis, frontotemporal lobar dementia, and non-demented human controls","volume":"35","author":"Hebert","year":"2013","journal-title":"J. Alzheimer's Dis"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"208","DOI":"10.5582\/ddt.2025.01055","article-title":"The pTau217\/Abeta(1-42) plasma ratio: the first FDA-cleared blood biomarker test for diagnosis of Alzheimer's disease","volume":"19","author":"Hu","year":"2025","journal-title":"Drug Discov. Ther."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jalz.2011.03.004","article-title":"Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Jack","year":"2011","journal-title":"Alzheimers Dement."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s12916-021-02142-x","article-title":"Prediction of P-tau\/Abeta42 in the cerebrospinal fluid with blood microRNAs in Alzheimer's disease","volume":"19","author":"Jia","year":"2021","journal-title":"BMC Med."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.biopsych.2021.12.015","article-title":"Exosomal microRNA-based predictive model for preclinical Alzheimer's disease: a multicenter study","volume":"92","author":"Jia","year":"2022","journal-title":"Biol. Psychiatry"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41420-024-02283-x","article-title":"MiRNAs as major players in brain health and disease: current knowledge and future perspectives","volume":"11","author":"Kapplingattu","year":"2025","journal-title":"Cell Death Discov."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"7479","DOI":"10.1002\/alz.14157","article-title":"The plasma miRNAome in ADNI: signatures to aid the detection of at-risk individuals","volume":"20","author":"Kruger","year":"2024","journal-title":"Alzheimers Dement."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"e69807","DOI":"10.1371\/journal.pone.0069807","article-title":"Circulating miRNA biomarkers for Alzheimer's disease","volume":"8","author":"Kumar","year":"2013","journal-title":"PLoS One"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1002\/alz.13055","article-title":"MicroRNA expression in extracellular vesicles as a novel blood-based biomarker for Alzheimer's disease","volume":"19","author":"Kumar","year":"2023","journal-title":"Alzheimers Dement."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"R78","DOI":"10.1186\/gb-2013-14-7-r78","article-title":"A blood based 12-miRNA signature of Alzheimer disease patients","volume":"14","author":"Leidinger","year":"2013","journal-title":"Genome Biol."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41531-023-00628-4","article-title":"Candidate biomarkers of EV-microRNA in detecting REM sleep behavior disorder and Parkinson's disease","volume":"10","author":"Li","year":"2024","journal-title":"NPJ Parkinsons Dis"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"880997","DOI":"10.3389\/fgene.2022.880997","article-title":"Identifying key MicroRNA signatures for neurodegenerative diseases with machine learning methods","volume":"13","author":"Li","year":"2022","journal-title":"Front. Genet."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.neuroscience.2020.02.044","article-title":"Profile of pathogenic proteins and MicroRNAs in plasma-derived extracellular vesicles in Alzheimer's disease: a pilot study","volume":"432","author":"Li","year":"2020","journal-title":"Neuroscience"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.gpb.2019.09.004","article-title":"Machine learning to detect Alzheimer's disease from circulating non-coding RNAs","volume":"17","author":"Ludwig","year":"2019","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"e0139233","DOI":"10.1371\/journal.pone.0139233","article-title":"Plasma Exosomal miRNAs in persons with and without Alzheimer disease: altered expression and prospects for biomarkers","volume":"10","author":"Lugli","year":"2015","journal-title":"PLoS One"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.neurobiolaging.2025.03.014","article-title":"Brain microRNAs differentially expressed in age-related cerebral pathologies","volume":"151","author":"Luo","year":"2025","journal-title":"Neurobiol. Aging"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.3233\/JAD-160835","article-title":"MicroRNAs in human cerebrospinal fluid as biomarkers for Alzheimer's disease","volume":"55","author":"Lusardi","year":"2017","journal-title":"J. Alzheimer's Dis"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"16122","DOI":"10.18632\/oncotarget.15109","article-title":"Profile of 6 microRNA in blood plasma distinguish early stage Alzheimer's disease patients from non-demented subjects","volume":"8","author":"Nagaraj","year":"2017","journal-title":"Oncotarget"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.brainres.2017.11.009","article-title":"MicroRNA expression patterns in human anterior cingulate and motor cortex: a study of dementia with Lewy bodies cases and controls","volume":"1678","author":"Nelson","year":"2018","journal-title":"Brain Res."},{"key":"ref47","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3389\/fnins.2020.00438","article-title":"Differential expression of plasma exo-miRNA in neurodegenerative diseases by next-generation sequencing","volume":"14","author":"Nie","year":"2020","journal-title":"Front. Neurosci."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1007\/s00259-019-04480-8","article-title":"Diagnostic accuracy of DAT-SPECT and MIBG scintigraphy for dementia with Lewy bodies: an updated systematic review and Bayesian latent class model meta-analysis","volume":"47","author":"Nihashi","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.3390\/genes13061034","article-title":"Differentially expressed miRNAs in age-related neurodegenerative diseases: a meta-analysis","volume":"13","author":"Noronha","year":"2022","journal-title":"Genes (Basel)"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.3390\/biom10060945","article-title":"Circulating inflammatory miRNAs associated with Parkinson's disease pathophysiology","volume":"10","author":"Oliveira","year":"2020","journal-title":"Biomolecules"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1515\/jci-2020-0013","article-title":"When is a match sufficient? A score-based balance metric for the synthetic control method","volume":"8","author":"Parast","year":"2020","journal-title":"J. Causal Infer."},{"key":"ref52","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.parkreldis.2019.04.010","article-title":"Combinatory microRNA serum signatures as classifiers of Parkinson's disease","volume":"64","author":"Patil","year":"2019","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref53","doi-asserted-by":"publisher","first-page":"15589","DOI":"10.1038\/s41598-022-19862-6","article-title":"Plasma microRNAs as potential biomarkers in early Alzheimer disease expression","volume":"12","author":"Pena-Bautista","year":"2022","journal-title":"Sci. Rep."},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1002\/mds.27362","article-title":"Validation of the MDS clinical diagnostic criteria for Parkinson's disease","volume":"33","author":"Postuma","year":"2018","journal-title":"Mov. Disord."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"4404","DOI":"10.1096\/fj.201801846R","article-title":"Down-regulated expression of microRNA-338-5p contributes to neuropathology in Alzheimer's disease","volume":"33","author":"Qian","year":"2019","journal-title":"FASEB J."},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1212\/CON.0000000000001497","article-title":"Fluid biomarkers in dementia diagnosis","volume":"30","author":"Quinn","year":"2024","journal-title":"Continuum (Minneap Minn)"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"10118","DOI":"10.1007\/s12035-025-04890-w","article-title":"Plasma miRNA biomarker signatures in parkinsonian syndromes","volume":"62","author":"Ravanidis","year":"2025","journal-title":"Mol. Neurobiol."},{"key":"ref58","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1038\/s41598-025-33589-0","article-title":"Comparison of multi-miRNA models from donor-matched plasma and cerebrospinal fluid as candidate biomarkers for Alzheimer's disease prediction","volume":"16","author":"Sandau","year":"2025","journal-title":"Sci. Rep."},{"key":"ref59","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1038\/s41598-024-52681-5","article-title":"Analysis of the longitudinal stability of human plasma miRNAs and implications for disease biomarkers","volume":"14","author":"Sandau","year":"2024","journal-title":"Sci. Rep."},{"key":"ref60","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3233\/JAD-200396","article-title":"Performance of validated MicroRNA biomarkers for Alzheimer's disease in mild cognitive impairment","volume":"78","author":"Sandau","year":"2020","journal-title":"J. Alzheimer's Dis"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s42003-019-0324-7","article-title":"Risk prediction models for dementia constructed by supervised principal component analysis using miRNA expression data","volume":"2","author":"Shigemizu","year":"","journal-title":"Commun Biol"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12920-019-0607-3","article-title":"A comparison of machine learning classifiers for dementia with Lewy bodies using miRNA expression data","volume":"12","author":"Shigemizu","year":"","journal-title":"BMC Med. Genet."},{"key":"ref63","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/nan.12308","article-title":"Lewy- and Alzheimer-type pathologies in midbrain and cerebellum across the Lewy body disorders spectrum","volume":"42","author":"Sierra","year":"2016","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref64","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1136\/jnnp-2019-321111","article-title":"Neuropathology of dementia in patients with Parkinson's disease: a systematic review of autopsy studies","volume":"90","author":"Smith","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40035-016-0053-5","article-title":"miRNA expression profiles in cerebrospinal fluid and blood of patients with Alzheimer's disease and other types of dementia - an exploratory study","volume":"5","author":"Sorensen","year":"2016","journal-title":"Transl Neurodegener"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"681029","DOI":"10.3389\/fncel.2021.681029","article-title":"Editorial: synaptic loss and neurodegeneration","volume":"15","author":"Subramanian","year":"2021","journal-title":"Front. Cell. Neurosci."},{"key":"ref67","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.3233\/JAD-132144","article-title":"Genome-wide serum microRNA expression profiling identifies serum biomarkers for Alzheimer's disease","volume":"40","author":"Tan","year":"2014","journal-title":"J. Alzheimer's Dis"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"18344","DOI":"10.1074\/jbc.M110.112664","article-title":"MicroRNA-101 regulates amyloid precursor protein expression in hippocampal neurons","volume":"285","author":"Vilardo","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref69","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00401-010-0756-0","article-title":"Patterns of microRNA expression in normal and early Alzheimer's disease human temporal cortex: white matter versus gray matter","volume":"121","author":"Wang","year":"2011","journal-title":"Acta Neuropathol."},{"key":"ref70","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3233\/JAD-180539","article-title":"Validation of MicroRNA biomarkers for Alzheimer's disease in human cerebrospinal fluid","volume":"67","author":"Wiedrick","year":"2019","journal-title":"J. Alzheimer's Dis"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41531-022-00410-y","article-title":"Incidence of Parkinson disease in North America","volume":"8","author":"Willis","year":"2022","journal-title":"NPJ Parkinsons Dis"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"6147434","DOI":"10.1155\/2021\/6147434","article-title":"miR-101-3p contributes to alpha-Synuclein aggregation in neural cells through the miR-101-3p\/SKP1\/PLK2 pathway","volume":"2021","author":"Zhang","year":"2021","journal-title":"J Healthc Eng"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1373\/jalm.2019.029595","article-title":"A machine learning approach to identify a circulating MicroRNA signature for Alzheimer disease","volume":"5","author":"Zhao","year":"2020","journal-title":"J Appl Lab Med"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"758103","DOI":"10.3389\/fgene.2021.758103","article-title":"Identification of a qualitative signature for the diagnosis of dementia with Lewy bodies","volume":"12","author":"Zhou","year":"2021","journal-title":"Front. Genet."}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2026.1788991\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T05:35:24Z","timestamp":1786426524000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2026.1788991\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":74,"alternative-id":["10.3389\/fnagi.2026.1788991"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2026.1788991","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"article-number":"1788991"}}